
GLX Analytix is a personalized medicine company that utilizes a proprietary class of biomarkers combined with AI to bring personalized medicine to healthcare. Their GLX Signature technology identifies patterns of cleaved glycocalyx components from blood samples, acting as a fingerprint for active disease. This allows for earlier diagnosis before damage occurs, prediction of attacks, monitoring of treatment response, and serves as a companion diagnostic, accelerating drug development and market approval. They collaborate with clinicians across over 10 different chronic inflammatory diseases, aiming to improve patient lives worldwide by enabling earlier diagnosis, better treatment monitoring, and reduced hospitalizations.

GLX Analytix is a personalized medicine company that utilizes a proprietary class of biomarkers combined with AI to bring personalized medicine to healthcare. Their GLX Signature technology identifies patterns of cleaved glycocalyx components from blood samples, acting as a fingerprint for active disease. This allows for earlier diagnosis before damage occurs, prediction of attacks, monitoring of treatment response, and serves as a companion diagnostic, accelerating drug development and market approval. They collaborate with clinicians across over 10 different chronic inflammatory diseases, aiming to improve patient lives worldwide by enabling earlier diagnosis, better treatment monitoring, and reduced hospitalizations.